Yervoy injection 5mg/ml 40ml(ipilimumab)

Reference priceUSD $630.00Original source price: INR 52,500.00. Converted estimates are available by currency selection.

Brand	Yervoy
Manufacturer	Bristol-Myers Squibb GmbH & Co.KGaA
Prescription required	Yes

Description

Yervoy injection 5mg/ml 40ml(ipilimumab) is a medicine catalog record in the MediPriceHub database. Active ingredient: IPILIMUMAB. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Bristol-Myers Squibb GmbH & Co.KGaA. Therapeutic category: Medicine Library > Oncology Medicines > Malignant pleural mesothelioma. Pack information: 5 / 40. Origin country or market: United States. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.

Benefits

YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma Renal Cell Carcinoma (RCC) Colorectal Cancer Hepatocellular Carcinoma Non-Small Cell Lung Cancer (NSCLC) Malignant Pleural Mesothelioma Esophageal Cancer • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. • Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. • Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. • Treatment of adults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) as determined by an FDA-authorized test in combination with nivolumab. • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) as first-line treatment in combination with nivolumab. • in combination with nivolumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. • Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab. • Treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. • Treatment of adult patien

How to Use

Use IPILIMUMAB under the supervision of a qualified healthcare professional. It should be prepared and administered only by trained healthcare professionals in a setting appropriate for injectable or infusion medicines. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.

Specification

Active ingredient: IPILIMUMAB. Pack size: 5 / 40. Pack unit: bottle. Manufacturer: Bristol-Myers Squibb GmbH & Co.KGaA. Origin country: United States. Source category: Medicine Library > Oncology Medicines > Malignant pleural mesothelioma. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.

Side Effects

The available source record does not provide a clean, product-specific adverse-reaction list. Potential risks depend on the active ingredient, dose, route, treatment duration, and patient condition. Check the approved local prescribing information for the complete adverse-reaction profile, warnings, contraindications, and monitoring requirements. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, serious bleeding, or rapidly worsening symptoms.

This information is for reference only. Consult a qualified healthcare professional before using any medicine.